Next-gen obesity drug helps patients lose 28% of body weight
NEW YORK >> Eli Lilly said today its experimental obesity drug helped patients lose more than 28% of their weight over a year and a half in a key trial that allows the company to seek regulatory approval and potentially launch the next-generation drug next year.
Original Source
Read the full article at Staradvertiser →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.